Mast Therapeutics, Inc.
(NYSE Amex Equities : MSTX)

( )
MSTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading MSTX News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.78%71.571.0%$655.39m
AMGNAmgen Inc.
-1.27%153.800.8%$502.42m
CELGCelgene Corporation
-1.39%113.621.0%$465.54m
ARIAARIAD Pharmaceuticals, Inc.
0.02%23.7016.4%$429.03m
BIIBBiogen Inc.
-1.15%280.351.0%$389.15m
REGNRegeneron Pharmaceuticals, Inc.
0.13%363.412.5%$362.46m
ALXNAlexion Pharmaceuticals, Inc.
-1.12%134.352.5%$359.12m
ILMNIllumina, Inc.
-0.40%160.583.8%$225.19m
CLVSClovis Oncology, Inc.
0.87%57.1117.9%$163.62m
INCYIncyte Corporation
2.12%117.532.2%$153.09m
VRTXVertex Pharmaceuticals Incorporated
-1.95%80.912.1%$150.84m
TSROTESARO, Inc.
0.44%149.9115.0%$106.95m
SRPTSarepta Therapeutics, Inc.
-4.86%34.2316.8%$106.34m
IONSIonis Pharmaceuticals, Inc.
-0.93%46.708.9%$103.74m
BMRNBioMarin Pharmaceutical Inc.
-1.16%86.154.9%$100.55m

Company Profile

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.